Dianabol vs Survodutide
Well Studied vs Extensively Studied
avoid Mechanism-based · 60% Both Dianabol and Survodutide carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Dianabol Survodutide
Weight 300.44 Da ~4,500 Da
Half-life ~4-6 hours Approximately 6 days (109-115 hours)
Chain — 29 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Peptide with fatty acid acylation
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Research Evidence
Dianabol Survodutide
Status Well Studied Extensively Studied
References 5 studies 3 studies
Latest 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.